【诺诚健华盘中股价变动,核心产品获新批准】诺诚健华盘中涨超 3%,截至发稿,股价上涨 1.34%,现报 9.85 港元,成交额 1195.82 万港元。近日,诺诚健华公告称,其核心产品宜诺凯抑制剂获得中国国家药品监督管理局批准,用于一线治疗慢性淋巴细胞白血病╱小淋巴细胞淋巴瘤患者。奥布替尼也被《中国临床肿瘤学会淋巴瘤诊疗指南 2025》列为 CLL/SLL 一线治疗的 I 级推荐方案。此前,...
Source Link【诺诚健华盘中股价变动,核心产品获新批准】诺诚健华盘中涨超 3%,截至发稿,股价上涨 1.34%,现报 9.85 港元,成交额 1195.82 万港元。近日,诺诚健华公告称,其核心产品宜诺凯抑制剂获得中国国家药品监督管理局批准,用于一线治疗慢性淋巴细胞白血病╱小淋巴细胞淋巴瘤患者。奥布替尼也被《中国临床肿瘤学会淋巴瘤诊疗指南 2025》列为 CLL/SLL 一线治疗的 I 级推荐方案。此前,...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.